AbbVie completes acquisition of Landos Biopharma
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Theophylline is used to treat asthma and chronic obstructive pulmonary disease
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Launch of 20 new medicines expected by 2030
Additional data from APPRAISE ATP trial reinforce modular therapy approach
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
The award recognizes powerful science–industry collaborations for social good
Subscribe To Our Newsletter & Stay Updated